CytomX Therapeutics, Inc.
CTMX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $138,103 | $101,214 | $53,163 | $37,312 |
| % Growth | 36.4% | 90.4% | 42.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $138,103 | $101,214 | $53,163 | $37,312 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $83,382 | $77,680 | $111,649 | $114,194 |
| G&A Expenses | $29,726 | $30,018 | $42,849 | $39,160 |
| SG&A Expenses | $29,726 | $30,018 | $42,849 | $39,160 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $113,108 | $107,698 | $154,498 | $153,354 |
| Operating Income | $24,995 | -$6,484 | -$101,335 | -$116,042 |
| % Margin | 18.1% | -6.4% | -190.6% | -311% |
| Other Income/Exp. Net | $7,098 | $9,807 | $2,018 | $172 |
| Pre-Tax Income | $32,093 | $3,323 | -$99,317 | -$115,870 |
| Tax Expense | $224 | $3,892 | $0 | $0 |
| Net Income | $31,869 | -$569 | -$99,317 | -$115,870 |
| % Margin | 23.1% | -0.6% | -186.8% | -310.5% |
| EPS | 0.38 | -0.008 | -1.48 | -1.26 |
| % Growth | 5,035.1% | 99.5% | -17.5% | – |
| EPS Diluted | 0.38 | -0.008 | -1.48 | -1.26 |
| Weighted Avg Shares Out | 84,439 | 73,808 | 65,740 | 64,147 |
| Weighted Avg Shares Out Dil | 84,745 | 73,808 | 65,740 | 64,147 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,136 | $9,837 | $1,678 | $255 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,768 | $2,175 | $2,443 | $2,706 |
| EBITDA | $26,763 | -$4,309 | -$98,892 | -$113,336 |
| % Margin | 19.4% | -4.3% | -186% | -303.8% |